Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 26, Issue 2, 2009, Pages 121-131

  Park, M K ^a   Fontana, J R ^a   Babaali, H ^a   Gilbert McClain, L I ^a   Stylianou, M ^a   Joo, J ^a   Moss, J ^a   Manganiello, Vincent C ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Pentoxifylline; Phosphodiesterase; Pulmonary function; Sarcoidosis; Steroid sparing

Indexed keywords

CYTOKINE; PENTOXIFYLLINE; PLACEBO; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG FUNCTION TEST; LUNG SARCOIDOSIS; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY FLOW RATES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77649240656     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357 (21): 2153-65.
2. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003; 361 (9363): 1111-8.
3. Ziegenhagen MW, Schrum S, Zissel G, Zipfel PF, Schlaak M, Muller-Quernheim J. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J Investig Med 1998; 46 (5): 223-31.
4. Capelli A, Di SA, Lusuardi M, Gnemmi I, Donner CF. Increased macrophage inflammatory protein-1alpha and macrophage inflammatory protein-1beta levels in bronchoalveolar lavage fluid of patients affected by different stages of pulmonary sarcoidosis. Am J Respir Crit Care Med 2002; 165 (2): 236-41.
5. Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta. Science 1993; 260 (5106): 355-8.
6. Petrek M, Pantelidis P, Southcott AM, et al. The source and role of RANTES in interstitial lung disease. Eur Respir J 1997; 10 (6): 1207-16.
7. Agostini C, Meneghin A, Semenzato G.T-lymphocytes and cytokines in sarcoidosis. Curr Opin Pulm Med 2002; 8 (5): 435-40.
8. Gerke AK, Hunninghake G. The immunology of sarcoidosis. Clin.Chest Med 2008; 29 (3): 379-90.
9. Baughman RP, Strohofer SA, Buchsbaum J, Lower EE. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990; 115 (1): 36-42.
10. Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Muller-Quernheim J. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997; 156 (5): 1586-92.
11. Shigehara K, Shijubo N, Ohmichi M, et al. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J Immunol 2001; 166 (1): 642-9.
12. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007; 76: 481-511.
13. Sanz MJ, Cortijo J, Morcillo EJ. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. Pharmacol Ther 2005; 106 (3): 269-97.
14. Lauterbach R, Pawlik D, Zembala M, et al. Pentoxyfylline in and prevention and treatment of chronic lung disease. Acta Paediatr Suppl 2004; 93 (444): 20-2.
15. Thanhauser A, Reiling N, Bohle A, et al. Pentoxifylline: a potent inhibitor of IL-2 and IFN-gamma biosynthesis and BCG-induced cytotoxicity. Immunology 1993; 80 (1): 151-6.
16. Schandene L, Vandenbussche P, Crusiaux A, et al. Differential effects of pentoxifylline on the production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by monocytes and T cells. Immunology 1992; 76 (1): 30-4.
17. Prabhakar U, Lipshutz D,Truneh A. Inhibition of CD44, CD45 and LFA-3 mediated cytokine release from human monocytes by SK&F 86002 and pentoxifylline. Int J Immunopharmacol 1993; 15 (2): 205-9.
18. Rieckmann P,Weber F, Gunther A, et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 1996; 64 (2): 193-200.
19. Lauterbach R, Pawlik D, Kowalczyk D, Ksycinski W, Helwich E, Zembala M. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit Care Med 1999; 27 (4): 807-14.
20. Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. J Pharmacol Exp Ther 2002; 300 (2): 559-66.
21. Rao KM, Currie MS, McCachren SS, Cohen HJ. Pentoxifylline and other methyl xanthines inhibit interleukin-2 receptor expression in human lymphocytes. Cell Immunol 1991; 135 (2): 314-25.
22. Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155 (3): 1230-6.
23. Tong Z, Dai H, Chen B, Abdoh Z, Guzman J, Costabel U. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest 2003; 124 (4): 1526-32.
24. Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med 1999; 159 (2): 508-11.
25. Tong Z, Chen B, Dai H, Bauer PC, Guzman J, Costabel U. Extrinsic allergic alveolitis: inhibitory effects of pentoxifylline on cytokine production by alveolar macrophages. Ann Allergy Asthma Immunol 2004; 92 (2): 234-9.
26. Co DO, Hogan LH, Il-Kim S, Sandor M. T cell contributions to the different phases of granuloma formation. Immunol Lett 2004; 92 (1-2): 135-42.
27. Zissel G, Prasse A, Muller-Quernheim J. Sarcoidosis - immunopathogenetic concepts. Semin Respir Crit Care Med 2007; 28 (1): 3-14.
28. Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155 (5): 1665-9.
29. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis 1978; 118 (6 Pt 2): 1-120.
30. American Medical Association. Guides to the evaluation of permanent impairment. 4th ed. Chicago: American Medical Association; 1993: 153-7.
31. Mahler DA,Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93 (3): 580-6.
32. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis 1991; 144 (5): 1202-18.
33. Standardization of spirometry - 1987 update. Statement of the American Thoracic Society. Am Rev Respir Dis 1987; 136 (5): 1285-98.
34. O'Brien PC, Zhang D, Bailey K. Semi-parametric and non-parametric methods for clinical trials with incomplete data. Stat Med 2005; 24: 341-58.
35. Evaluation of impairment/disability secondary to respiratory disorders. American Thoracic Society. Am Rev Respir Dis 1986; 133 (6): 1205-9.
36. Sackett DL, Haynes R, Guyatt G,Tugwell P. Clinical Epidemiology: A Basic Science for Clinical Medicine. 2nd ed. Boston: Little, Brown and Company; 1991.
37. Sackett D, Richardson W, Rosenberg W, Haynes R. Evidenced-based Medicine. New York: Churchill Livingstone; 1997.
38. Baughman RP,Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17 (1): 60-6.
39. Wyser CP, van Schalkwyk EM, Alheit B, Bardin PG, Joubert JR. Treatment of progressive pulmonary sarcoidosis with cyclosporin A. A randomized controlled trial. Am J Respir Crit Care Med 1997; 156 (5): 1371-6.
40. Wang ML, Petsonk EL. Repeated measures of FEV1 over six to twelve months: what change is abnormal? J Occup Environ Med 2004; 46 (6): 591-5.
41. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174 (7): 795-802.
42. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009; 374 (9691): 695-703.
43. Bateman ED, Izquierdo JL, Harnest U, et al. Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol 2006; 96 (5): 679-86.